Another two phase III trials evaluating EGFR-tyrosine kinase inhibitors as maintenance therapy for advanced NSCLC patients, and found that erlotinib maintenance therapy significantly improved progress-free survival in comparison with placebo [24–26]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.